News

  • 14 January 2011

    Endosense, a Swiss medical technology company, and Siemens Healthcare, one of the world’s largest suppliers to the healthcare industry, have agreed to commence a joint development project intended to integrate the contact-force data provided by Endosense’s TactiCath® force-sensing ablation catheter with Siemens’ electrophysiology solutions. The goal of the effort is to develop a technologically advanced, all-in-one software application that allows electrophysiologists to visualize catheter tip-to- tissue contact force within a three-dimensional anatomic heart model during catheter ablation procedures.

  • 24 December 2010

    Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, has signed a license agreement with Ethicon, Inc., related to its fibrin-based technologies.

  • 15 December 2010

    Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis.

  • 8 November 2010

    Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has regained rights to a number of selected wound care and trauma clinical candidates that were previously licensed to Baxter International Inc.

  • 7 October 2010

    Richter announces the Acquisition of PregLem for an initial cash consideration of CHF150 million (€114 million) and further milestone payments of up to CHF295 million (€223 million). The Acquisition values PregLem at up to CHF445 million (€337 million)